For the Inventor, By the Inventor

Enter assignee name

Brisbane, CA, United States of America

Myokardia, Inc.

USPTO Granted Patents = 12

EPO Patents = 4

Trademarks = 7

Forward Citations = 51

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Johan D Oslob (10 out of 38 patents)

Yonghong Song (8 out of 61 patents)

Danielle Aubele (8 out of 11 patents)

4. Robert S McDowell (8 out of 69 patents)

5. Arvinder Sran (7 out of 27 patents)

6. Min Zhong (7 out of 41 patents)

7. Brian Kane (7 out of 18 patents)

8. Marc Evanchik (5 out of 18 patents)

9. Jonathan Charles Fox (5 out of 5 patents)

10. Hector Rodriguez (4 out of 10 patents)

11. Robert G Anderson (4 out of 77 patents)

12. Jae Kim (3 out of 3 patents)

13. Mark Grillo (3 out of 4 patents)

14. Puping Lu (3 out of 3 patents)

15. Fabienne Thompson (2 out of 15 patents)

12 patents: Sort by Forward Citations

1. 12459919 - Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1- fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide (2025-11-04),

2. 12344607 - Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases (2025-07-01),

3. RE50050 - Pyrimidinedione compounds (2024-07-23),

4. 11873289 - Pyrazole compounds and preparation thereof (2024-01-16),

5. 11123337 - 4-methylsulfonyl-substituted piperidine urea compounds (2021-09-21),

6. 11034693 - Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases (2021-06-15),

7. 10758525 - 4-methylsulfonyl-substituted piperidine urea compounds (2020-09-01),

8. 9925177 - 4-methylsulfonyl-substituted piperidine urea compounds (2018-03-27),

9. 9663516 - Bicyclic-pyrimidinedione compounds (2017-05-30),

10. 9585883 - Pyrimidinedione compounds (2017-03-07),

11. 9199945 - Cycloalkyl-substituted pyrimidinedione compounds (2015-12-01),

12. 9181200 - Pyrimidinedione compounds (2015-11-10),

Myokardia is a biopharmaceutical company focused on discovering, developing and commercializing targeted therapies for the treatment of serious cardiovascular diseases. The company's lead candidate, mavacamten, is being developed for the treatment of hypertrophic cardiomyopathy, a genetic heart condition. Myokardia is dedicated to improving the lives of patients with cardiovascular diseases through innovative therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

12 Patents

#11 in Brisbane, CA

#5,875 in California

#24,782 in US

#46,701 in the World

Brisbane, CA, United States of America

Myokardia, Inc.

Forward Citations = 51

29 inventors:

Johan D Oslob (10 out of 38 patents)

Yonghong Song (8 out of 61 patents)

Danielle Aubele (8 out of 11 patents)

4. Robert S McDowell (8 out of 69 patents)

5. Arvinder Sran (7 out of 27 patents)

Please report any incorrect information to support@idiyas.com

Loading…